Loading
A phase 3 trial of Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations. ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is actual at 1350 participants. Primary completion is estimated at 2027-11-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel. Registered primary measures: Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population; Overall Survival (OS) in the non-squamous TROP2 biomarker positive population; PFS by BICR in the non-squamous population.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Platinum agents and the tag pipeline.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares TROP2, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Datopotamab deruxtecan, TROP2, Durvalumab, AstraZeneca and the tag pipeline.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/